Volume | 41 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Quanterix Corporation | QTRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
14.52 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
3 | 41 | - | 14.255 - 29.70 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
04:47:07 | 30 | US$ 14.41 | USD |
Quanterix Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
552.68M | 38.06M | - | 122.37M | -32.33M | -0.85 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Quanterix News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QTRX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.90 | 19.175 | 14.52 | 16.83 | 776,837 | -1.38 | -8.68% |
1 Month | 17.42 | 19.175 | 14.52 | 16.47 | 434,877 | -2.90 | -16.65% |
3 Months | 24.02 | 24.87 | 14.255 | 17.68 | 427,710 | -9.50 | -39.55% |
6 Months | 25.60 | 29.70 | 14.255 | 21.24 | 372,287 | -11.08 | -43.28% |
1 Year | 22.96 | 29.70 | 14.255 | 22.53 | 370,843 | -8.44 | -36.76% |
3 Years | 65.97 | 69.22 | 6.31 | 22.24 | 378,549 | -51.45 | -77.99% |
5 Years | 34.21 | 92.57 | 6.31 | 28.54 | 323,915 | -19.69 | -57.56% |
Quanterix Description
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability. |